Testosterone

Generic Name: Testosterone

Brand Names: Androderm, Androgel, Axiron, Fortesta, Natesto, Striant, Testim, Testopel, Vogelxo

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₈O_₂

CAS Number: 58-22-0

Unique Ingredient Identifier: 3XMK78S47O

Background: Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism. Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.

Testosterone was isolated from samples and also synthesized in 1935.

Indication: Testosterone is indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.

Associated Conditions: Hypergonadotropic Hypogonadism, Hypogonadotrophic Hypogonadism, Idiopathic Hypogonadotropic Hypogonadism, Puberty, Delayed, Inoperable, metastatic Breast cancer

Associated Therapies: -

Clinical Trials

Testosterone Replacement in Diabetes With Vascular Disease (Version 2)

Phase 4

Completed

Conditions: Diabetes Mellitus
Peripheral Vascular Disease

Interventions: Drug: 0.9% saline
Drug: Testosterone

First Posted Date: 2006-07-24

Last Posted Date: 2010-03-30

Lead Sponsor: Barnsley Hospital

Target Recruit Count: 19

Registration Number: NCT00355537

Locations: 🇬🇧
Barnsley Hospital NHS Foundation Trust, Barnsley, South Yorkshire, United Kingdom

Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception

Phase 2

Completed

Conditions: Pain
Hypogonadism

Interventions: Drug: AndroGel
Other: Placebo

First Posted Date: 2006-07-13

Last Posted Date: 2017-06-28

Lead Sponsor: Boston University

Target Recruit Count: 84

Registration Number: NCT00351819

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Effect of Androgel on Type 2 Diabetic Males With Hypogonadism

Phase 4

Completed

Conditions: Diabetes Mellitus Type 2

Interventions: Drug: androgel 10g
Drug: placebo
Drug: androgel

First Posted Date: 2006-07-11

Last Posted Date: 2022-02-10

Lead Sponsor: University at Buffalo

Target Recruit Count: 49

Registration Number: NCT00350701

Locations: 🇺🇸
Diabetes-Endocrinology Center of Western NY, 115 flint road, Buffalo, New York, United States

Testosterone for Men With Insulin Treated Type 2 Diabetes

Phase 4

Completed

Conditions: Hypogonadism
Diabetes

Interventions: Drug: 0.9% saline
Drug: Testosterone

First Posted Date: 2006-07-07

Last Posted Date: 2010-03-30

Lead Sponsor: Barnsley Hospital

Target Recruit Count: 40

Registration Number: NCT00349362

Locations: 🇬🇧
Barnsley Hospital NHS Foundation Trust, Barnsley, South Yorkshire, United Kingdom

Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men

Phase 1

Completed

Conditions: Aging

Interventions: Drug: Placebo
Drug: Testosterone
Drug: Anastrazole
Drug: Dutasteride

First Posted Date: 2006-04-03

Last Posted Date: 2012-07-31

Lead Sponsor: Mayo Clinic

Target Recruit Count: 80

Registration Number: NCT00309855

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Does Testosterone Improve Function in Hypogonadal Older Men

Phase 4

Withdrawn

Conditions: Hypogonadism

First Posted Date: 2006-03-17

Last Posted Date: 2015-02-13

Lead Sponsor: North Florida Foundation for Research and Education

Registration Number: NCT00304213

Locations: 🇺🇸
Nf/Sg Vhs, Gainesville, Florida, United States

Co-Administering Testosterone With PDE5 Inhibitors in ED Patients Non Responders to PDE5 Inhibitors Alone

Phase 3

Completed

Conditions: Erectile Dysfunction
Hypogonadism

Interventions: Drug: Testosterone gel
Other: placebo gel
Drug: testosterone

First Posted Date: 2005-10-25

Last Posted Date: 2008-08-25

Lead Sponsor: SELARL du Dr Jacques BUVAT

Target Recruit Count: 173

Registration Number: NCT00244023

Locations: 🇫🇷
CETPARP/SelarlJBuvat, Lille, France

ANDRO 2002: Dehydroepiandrosterone (DHEA) or Testosterone Versus Placebo in Men With Sexual Dysfunction

Phase 2

Completed

Conditions: Erectile Dysfunction

First Posted Date: 2005-09-20

Last Posted Date: 2016-01-13

Lead Sponsor: Queen's University

Target Recruit Count: 120

Registration Number: NCT00202163

Locations: 🇨🇦
Centre for Advanced Urological Research, Kingston, Ontario, Canada

Testosterone Effects on Bone and Frailty

Phase 4

Completed

Conditions: Aging
Frailty
Osteoporosis

First Posted Date: 2005-09-16

Last Posted Date: 2009-10-30

Lead Sponsor: National Institute on Aging (NIA)

Target Recruit Count: 140

Registration Number: NCT00182871

Locations: 🇺🇸
Center on Aging, University of Connecticut Health Center, Farmington, Connecticut, United States

Dose-Response of Gonadal Steroids and Bone Turnover in Older Men

Not Applicable

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Testosterone
Drug: Goserelin acetate

First Posted Date: 2005-06-14

Last Posted Date: 2019-10-08

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 177

Registration Number: NCT00114114

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy